Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 12:30:173-181.
doi: 10.1016/j.reth.2025.05.011. eCollection 2025 Dec.

Mesenchymal stem cell for hemorrhagic stroke: A clinical review

Silvia de la Calle  1 , Mercedes Zurita  2
Affiliations
Review

Mesenchymal stem cell for hemorrhagic stroke: A clinical review

Silvia de la Calle et al. Regen Ther. .

Abstract

Hemorrhagic stroke, which is also called an intracerebral hemorrhage, is a cerebrovascular disease that represents a serious public health problem worldwide. Among all types of stroke, intracerebral hemorrhage causes the highest percentage of mortality and morbidity, affecting 2 million people annually, with no specific treatment established except for rehabilitation-oriented techniques. In recent years, new alternatives have been sought to treat this type of pathology, with mesenchymal stem cell therapy gaining special relevance. These cells present a series of biological properties, including regenerative repair, neuroprotection, and immunomodulation that make them a tool with enormous potential in regenerative medicine. In this review, we are going to focus on clinical trials and clinical studies which use cell therapy with Mesenchymal Stem Cells as a treatment for patients suffering from intracerebral hemorrhage. The clinical trials found are not very numerous. It remains an area to be explored; however, existing studies suggest it is a safe therapy that yields positive neurological and functional outcomes in many treated patients. All of this makes it a very promising and encouraging therapy for patients with this type of pathology.

Keywords: Cell therapy; Hemorrhagic stroke; Intracerebral hemorrhage; Mesenchymal stem cells and clinical trials.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
ICH pathophysiology.
Fig. 2
Fig. 2
PRISMA flow diagram [56].
See this image and copyright information in PMC

References

    1. Díez-Tejedor E., del Brutto O., Alvarez Sabín J., Muñoz M., Abiusi G. [Classification of the cerebrovascular diseases. Iberoamerican Cerebrovascular diseases Society] Rev Neurol. 2001;33:455–464. - PubMed
    1. Chang Z., Mao G., Sun L., Ao Q., Gu Y., Liu Y. 2016. Cell therapy for cerebral hemorrhage : five year follow-up report; pp. 3535–3540. - DOI - PMC - PubMed
    1. Bedini G., Bersano A., Zanier E.R., Pischiutta F., Parati E.A. 2018. Mesenchymal stem cell therapy in intracerebral haemorrhagic stroke; pp. 2176–2197. - DOI - PubMed
    1. Fernando S.M., Qureshi D., Talarico R., Tanuseputro P., Dowlatshahi D., Sood M.M., et al. 2021. Intracerebral hemorrhage incidence , mortality , A population study; pp. 1673–1681. - DOI - PubMed
    1. Turnbull M.T., Zubair A.C., Meschia J.F., Freeman W.D. Mesenchymal stem cells for hemorrhagic stroke : status of preclinical and clinical research. NPJ Regen Med. 2019:1–10. doi: 10.1038/s41536-019-0073-8. - DOI - PMC - PubMed

LinkOut - more resources